About Careers MedBlog Contact us

Inhaled Corticosteroids Boost Pneumonia Risk in COPD Patients

by VR Sreeraman on November 26, 2008 at 11:56 AM
Font : A-A+

 Inhaled Corticosteroids Boost Pneumonia Risk in COPD Patients

Using inhaled corticosteroids to treat chronic obstructive pulmonary disease (COPD) significantly increases the risk of pneumonia in patients, a report published Tuesday showed.

Researchers who reviewed and analyzed 11 randomized controlled trials involving 14,426 participants also found that inhaled corticosteroid (ICS) therapy did not improve survival rates of sufferers of COPD, a smoking-related lung disease.


"ICS therapy was associated with a 34 percent increased risk of pneumonia," the research team from Johns Hopkins University in the US state of Maryland and the University of Manitoba in Canada wrote in the November 26 edition of the Journal of the American Medical Association (JAMA).

Furthermore, the higher the dose of ICS, the greater the risk of pneumonia, the report said.

"Recognizing the adverse events associated with ICS use is especially important since clinicians may increase ICS therapy from moderate to high doses in patients who are not responding," the researchers wrote.

"Our data suggest that increasing to higher ICS doses may place patients at greater risk of pneumonia," they wrote.

Patients with low exhalation volume, on combination therapy, where corticosteroids are administered along with another treatment, and those on short-duration ICS therapy were also at greater risk of contracting pneumonia when using inhaled corticosteroids, according to the report.

The researchers, who were unable to clearly determine why ICS therapy increases pneumonia risk, also found that using inhaled corticosteroids does not improve survival rates for COPD, which is the fourth leading cause of death in the United States.

The only interventions which improve survival rates among COPD patients are quitting smoking and supplemental oxygen, according to the report.

Characterized by bouts of coughing, sputum production and breathlessness, COPD affects 10-15 million people and claims 120,000 lives each year in the United States.

Inhaled corticosteroid therapy is used only to reduce symptoms and complications associated with COPD, according to the report.

Source: AFP


Recommended Reading

Latest Respiratory Disease News

Emerging Respiratory Threat - Human Metapneumovirus (HMPV)
According to the Centers for Disease Control and Prevention (CDC), there was a notable increase in infections caused by human metapneumovirus (HMPV), an emerging threat.
Is Lab-Grown Mini Lungs the Key to Understanding Respiratory Diseases?
The new cell culture technology platform allows researchers to react to the next pandemic with much more speed and precision.
 Artificial Intelligence-enabled Chest Scan Improves Pulmonary Hypertension Diagnosis
A new artificial intelligence-enabled chest imaging technology performs a deep characterization of the pulmonary vasculature to detect pulmonary (arterial) hypertension.
Could a Severe Heatwave Lead to Asthma?
The global climate crisis is stimulating heat waves to become more frequent causing distress to people with asthma, say experts.
Why Is Vitamin D3 Essential for Allergic Asthma?
A new study reveals vitamin D3 supplements have encouraging effects for asthma patients. Vitamin D has a positive effect on immune response.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

Inhaled Corticosteroids Boost Pneumonia Risk in COPD Patients Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests